BioSpace News Archive

Solid Biosciences Inc. today provided an update from the ongoing IGNITE DMD Phase I/II clinical trial, as well as a business and financial update.

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that on March 11, 2022, the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3 clinical trial investigating the use of Tempol for the treatment of COVID-19, met to evaluate the clinical and safety data from the first planned interim analysis.

Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura™) for the treatment of vitiligo.

Biomea Fusion, Inc. (Nasdaq: BMEA), today announced that an abstract has been accepted at the upcoming American Diabetes Association (ADA) 82nd Scientific Sessions.

BiondVax Pharmaceuticals Ltd. announced that it had been negotiating with the European Investment Bank terms of restructuring of its outstanding €24 million loan.

GreenLight Biosciences Holdings PBC today announced a licensing agreement with Serum Institute of India, Pvt, Ltd., aimed at accelerating accessibility to messenger RNA products in emerging markets globally.

MediLink Therapeutics Co., Ltd recently announced completion of a US$70 million Series B financing.

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the engagement of CATO SMS to manage GeoVax’s two ongoing Phase 2 clinical trials of its vaccine candidate, GEO-CM04S1, against SARS-CoV-2.

Amsterdam, the Netherlands and Orlando, Florida, USA – Royal Philips, a global leader in health technology, will showcase its latest secure, connected and scalable informatics solutions during the HIMSS22 Global Health Conference & Exhibition.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study, “A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression.”